Medline Inc.
MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3068% above fair value
$37.84−1.32 (-3.37%)
Close on Nov 19, 2026Market cap $49.75BP/E –Yield –
Medline Trailing-Twelve-Month Adjusted EBITDA by Quarter
Trailing-Twelve-Month Adjusted EBITDA ($M)
Medline Trailing-Twelve-Month Adjusted EBITDA: $3,601M in Q3 2026.
Latest, Q3 2026
3,601
Period ended Sep 30, 2026
Change on a year earlier
–
History
5 quarters
Since Q4 2024
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
Source: SEC Form 8-K Ex. 99.1 Q3 2026 Earnings Release (2026-11-04) ↗
Reported in SEC Form 8-K Earnings Releases.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trailing-Twelve-Month Adjusted EBITDA ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 3,601 | – | SEC Form 8-K Ex. 99.1 Q3 2026 Earnings Release (2026-11-04) ↗ |
| Q2 2026 | Jun 30, 2026 | 3,500 | – | SEC Form 8-K Ex. 99.1 Q2 2026 Earnings Release (2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,375 | – | SEC Form 8-K Ex. 99.1 Q1 2026 Earnings Release (2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,467 | +3.2% | SEC Form 8-K Ex. 99.1 Q4 & FY2025 Earnings Release (2026-02-25) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,361 | – | SEC Form 8-K Ex. 99.1 Q4 & FY2025 Earnings Release (2026-02-25) ↗ |
Cite this data
StockData. (2026). Medline Trailing-Twelve-Month Adjusted EBITDA ($M), quarterly Q4 2024–Q3 2026 [Data set]. Compiled from Medline SEC filings and investor materials. https://stockdatahq.com/stocks/mdln/kpis/cap-ttm-adj-ebitda
See every metric in the Medline KPI table. Data updated Nov 7, 2026.
See a number that looks wrong?